tiprankstipranks
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
US Market
FULC
Fulcrum Therapeutics
RESEARCH TOOLSreports

Fulcrum Therapeutics (FULC) Stock News & Sentiment

520 Followers
Regulatory Tailwinds and Clinical Momentum Support Buy Rating on Fulcrum Ahead of Key 2Q26 FDA Milestones
Premium
Ratings
Regulatory Tailwinds and Clinical Momentum Support Buy Rating on Fulcrum Ahead of Key 2Q26 FDA Milestones
9d ago
FULC
Fulcrum Extends Pociredir Program With Long-Term Sickle Cell Study
Premium
Company Announcements
Fulcrum Extends Pociredir Program With Long-Term Sickle Cell Study
20d ago
FULC
Fulcrum Therapeutics Charts Pivotal Path After Earnings Call
Premium
Company Announcements
Fulcrum Therapeutics Charts Pivotal Path After Earnings Call
1M ago
FULC
Fulcrum Therapeutics (FULC) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Fulcrum Therapeutics (FULC) Q4 Earnings Cheat Sheet
2M ago
FULC
Pociredir’s Emerging Strength in Sickle Cell Disease Positions FULC for Upside Ahead of 1Q26 Data
Premium
Ratings
Pociredir’s Emerging Strength in Sickle Cell Disease Positions FULC for Upside Ahead of 1Q26 Data
2M ago
FULC
Fulcrum’s Pociredir Trial Completion Adds a New Catalyst to the Sickle Cell Investment Story
Premium
Company Announcements
Fulcrum’s Pociredir Trial Completion Adds a New Catalyst to the Sickle Cell Investment Story
2M ago
FULC
De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data
Premium
Ratings
De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data
2M ago
FULC
More FULC News >

FULC News on the Web

Leerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update
TipRanks News
Neutral
Regulatory Tailwinds and Clinical Momentum Support Buy Rating on Fulcrum Ahead of Key 2Q26 FDA Milestones
TipRanks News
Neutral
Fulcrum Extends Pociredir Program With Long-Term Sickle Cell Study
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Fulcrum Therapeutics (FULC)
TipRanks News
Neutral
Fulcrum Therapeutics enters partnership for emergency sickle cell disease care
TipRanks News
Neutral
Fulcrum Therapeutics Grants 34,000 Stock Options to New Hire—What This Signals About Company Growth
Market Chameleon
Neutral
Fulcrum Therapeutics Charts Pivotal Path After Earnings Call
TipRanks News
Bullish
RBC Capital Remains a Hold on Fulcrum Therapeutics (FULC)
TipRanks News
Bearish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is FULC’s Media Buzz Sentiment?
Currently, no data Available
What is FULC’s weekly average amount of articles?
Currently, no data Available
What is FULC’s News Sentiment?
Currently, no data Available
Healthcare Stocks that are Trending in the News
NBIXNeurocrine
STAAStaar Surgical
AORTArtivion
OWLTOwlet
HUMHumana
Showing the stocks with the most bullish news sentiment over the past week